Clinical trial Recruiting at 1 site Observational Ages 18 and up

Suture mucopexy plus laser treatment for moderate-to-severe hemorrhoids

Official title: Prospective Evaluation of Hemorrhoid Suture Mucopexy (SM) Combined With Laser Hemorrhoidoplasty (LHP) for Symptomatic Hemorrhoidal Disease: A Cohort Study

Run by National and Kapodistrian University of Athens · NCT07404774 · Data updated 2026-11-12

This study will test whether adding a stitch-based mucosal lift to laser hemorrhoidoplasty reduces pain, bleeding, and prolapse in adults with moderate-to-severe (Grade II–IV) hemorrhoids.

More Haemorrhoid trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment100 (estimated)
SponsorNational and Kapodistrian University of Athens
Academic / other
Locations1 site (Athens)
StatusRecruiting
StartedJanuary 1, 2026
Main results expectedJanuary 2028
Study endsJanuary 2029
Registry record updatedFebruary 11, 2026
Trial IDNCT07404774 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults over 18 with symptomatic hemorrhoidal disease (Goligher Grades II–IV), including those with prior non-stapled procedures, who can attend the Athens center are ideal candidates.

Probably not a fit

Patients with acutely thrombosed hemorrhoids, concurrent anal fistula or abscess requiring separate surgery, active rectal IBD, or prior stapled haemorrhoidopexy are excluded and unlikely to benefit from this approach.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center, prospective observational cohort in which all enrolled adults with Goligher Grade II–IV hemorrhoids receive a combined suture mucopexy and non‑Doppler laser hemorrhoidoplasty. The combined procedure aims to remove mucosal prolapse and ligate feeding vessels while preserving the low-pain recovery profile of laser treatment. Participants are followed at 6 weeks, 6 months, and 12 months to record pain medication use, time to complete symptom relief, quality of life, safety events (bleeding, urinary retention, stenosis), and recurrence or re-operation. The approach is supported by preliminary feasibility data from 50 patients at the same center but is being evaluated formally in this prospective cohort.

Why it matters

Potential benefit: If successful, the combined technique could give faster symptom relief with fewer recurrences and fewer repeat operations while maintaining low post‑operative pain.

How similar studies have gone: Laser hemorrhoidoplasty is known for low‑pain recovery but higher recurrence in advanced prolapse, and single-center preliminary data (50 patients) suggest the mucopexy+LHP combination is feasible with low early complications, though larger prospective evidence is limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adults (\>18 years).
* Symptomatic Hemorrhoidal Disease (Goligher Grades II, III, IV).
* Patients with or without recurrent disease after prior procedures (e.g., RBL, infrared coagulation, Milligan-Morgan, etc).

Exclusion Criteria:

* Acutely thrombosed hemorrhoids.
* Concomitant anal fistula or abscess requiring separate surgical management.
* IBD (Crohn's/Ulcerative Colitis) with active rectal involvement.
* Previous Stapled Haemorrhoidopexy (SH/Longo).

Where it's running

  • Ippokrateio Hospital
    Athens, Greece
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.